New FAPI-46 PET scan for lobular breast cancer spread
Part of Cancer, Skin clinical trials.
This trial tests a new type of PET/CT scan (using a tracer called FAPI-46) to find cancer spread in people with lobular breast cancer. It may be an option if your standard scan was unclear or negative.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with invasive lobular breast cancer
- You had a standard FDG PET/CT scan that showed no clear cancer spots or was uncertain for at least one area
- You are not pregnant or breastfeeding
- You are not currently participating in another research study that has an exclusion period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special PET scan (F-FAPI PET) to image metastatic invasive lobular breast cancer. It aims to see if this scan gives a clearer picture than the standard PET scan, helping doctors track the cancer better.
This study tests a new kind of PET/CT scan that uses a tracer called 18F-FAPI to see if it can better detect cancer in the lymph nodes under the arm after you've already had chemotherapy or targeted therapy before surgery. If successful, this could help doctors plan more precise surgery and avoid removing unnecessary lymph nodes.
This study tests a new imaging agent (18F-FAPI-04) for PET scans to see if it can better detect breast cancer or its spread. It may help doctors find tumors more clearly.
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
This trial compares two types of PET scans to see which one better detects ER-positive breast cancer. The results could help doctors choose the best scan for tracking your cancer.
This trial tests a new imaging agent, [68Ga]Ga DOTA-5G, to see if it can better detect invasive lobular breast cancer that has spread to other parts of the body. It involves a PET/CT scan and may help doctors understand the extent of your cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.